JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $74 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on CRISPR Therapeutics (NASDAQ:CRSP) and maintained a $74 price target.
July 25, 2023 | 11:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CRISPR Therapeutics' stock rating has been reiterated as Market Outperform by JMP Securities, with a maintained price target of $74.
The reiteration of a Market Outperform rating by JMP Securities indicates a positive outlook for CRISPR Therapeutics. The maintained price target of $74 also suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100